Author

Rosie Adinin

Observed names: R. Adinin, R. B. Adinin, RB Adinin

Institutions: The University of Texas MD Anderson Cancer Center, The University of Texas at San Antonio Health Science Center, Universidade de São Paulo, Harris Health System, Instituto do Câncer do Estado de São Paulo, Lyndon Baines Johnson Hospital, Mebiopharm Co., Ltd. (Japan)

Observed institutions: The University of Texas MD Anderson Cancer Center, The University of Texas at San Antonio Health Science Center, Universidade de São Paulo, Harris Health System, Instituto do Câncer do Estado de São Paulo, Taiho Pharmaceutical (Japan), Taiho Oncology (United States), Lyndon Baines Johnson Hospital, Hospital Sírio-Libanês, Mebiopharm Co., Ltd. (Japan)

OpenAlex ID: A5113671938

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

2009 · Scott Kopetz, Paulo M. Hoff, et al. · Journal of Clinical Oncology · 485

A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin

2009 · K. K. Sankhala, A. C. Mita, et al. · Journal of Clinical Oncology · 84

Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)

2006 · M. C. Green, L. Pusztai, et al. · Journal of Clinical Oncology · 31

Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC)

2006 · S. Kopetz, J. L. Abbruzzese, et al. · Journal of Clinical Oncology · 22

Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer

2007 · S. Kopetz, K. Y. Glover, et al. · Journal of Clinical Oncology · 10

Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: Final results

2006 · E. Rivera, J. A. Mejia, et al. · Journal of Clinical Oncology · 5

Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel

2006 · S. R. Amin, V. Valero, et al. · Journal of Clinical Oncology · 5

Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater

2008 · M. J. Overman, G. R. Varadhachary, et al. · Journal of Clinical Oncology · 4

Two phase I, pharmacokinetic (PK) and pharmacodynamic (PD) studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules

2008 · K. K. Sankhala, C. H. Takimoto, et al. · Journal of Clinical Oncology · 3

Identification of Docetaxel in Tears from Patients with Metastatic Breast Cancer

2002 · Moloud Ahmadi, Bita Esmaeli, et al. · Investigative Ophthalmology & Visual Science · 2

Works count: 11

Citation count: 651

H-index: 5

I10-index: 5